ReviewReviews in endocrine & metabolic disorders2022
Pasireotide-a novel somatostatin receptor ligand after 20 years of use.
Review in Reviews in endocrine & metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Pooled it
- A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours.Endocrinology, diabetes & metabolism · 2024Pooled it
- Article
- Somatostatin in Aging: Correlations with Selected Central Nervous System and Gastrointestinal Tract Diseases.International journal of molecular sciences · 2026Review
- Post-bariatric Hypoglycemia Management: A Gulf Cooperation Council Consensus Statement.Journal of the Endocrine Society · 2026Article
- Tangeretin Suppresses LUAD via SSTR4 Downregulation: Integrated Bioinformatics and Functional Validation.International journal of molecular sciences · 2026Article
- Case Report: Paradoxical responses to pasireotide in a patient with a silent corticotroph adenoma that transformed into an ACTH-secreting adenoma.Frontiers in oncology · 2026Article
- Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response.Scientific reports · 2025Article
- Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions.Cancers · 2025Review
- Somatostatin Ameliorates Corneal Nerve Abnormalities and Inflammation Through Regulation of Macrophage Activities in Dry Eye Disease.Investigative ophthalmology & visual science · 2025Article
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.Diabetology & metabolic syndrome · 2025Article
- Somatostatin Analogs for Preventing Postoperative Pancreatic Fistula: Past Evidence Reveals New Opportunities.Annals of surgical oncology · 2025Review
- Protective Effects of Pasireotide in LPS-Induced Acute Lung Injury.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Efficacy and safety of pasireotide in patients with Cushing's disease: a monocentric experience.Endocrine · 2025Article
- Pasireotide Exerts Anti-Inflammatory Effects in the Endothelium.Journal of biochemical and molecular toxicology · 2025Article
- Clinical Implications of Molecular and Genetic Biomarkers in Cushing's Disease: A Literature Review.Journal of clinical medicine · 2025Review
- Exploring Macrocyclic Chemical Space: Strategies and Technologies for Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy in acromegaly than first-generation SRLs and to be efficacious in Cushing's disease. The consequence of this binding profile is the increased blood glucose level in some patients. This results from the inhibition of both insulin secretion and the incretin effect and only a modest suppression of glucagon. A monthly intramuscular formulation of long-acting release pasireotide has been approved for both acromegaly and Cushing's disease treatment. This review presents data on the efficacy and safety of pasireotide treatment mostly in patients with acromegaly and Cushing's disease. Moreover, other possible therapeutic applications of pasireotide are mentioned.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.